Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Non-Myeloablative T-Cell Depleted (TCD) Haploidentical Hematopoietic Cell Transplantation (HCT) Followed by Donor Leukocyte Infusion(s) for Hematologic Malignancies: The MGH Experience.

Bimalangshu R. Dey, MD, PhD, Andrew J. Yee, MD, Steven McAfee, MD, Christine Dube, Karen Ballen, MD, Eyal Attar, MD, Christine Colby, Susan Saidman, PhD, Karen Malikowski, Frederic Preffer, PhD, Megan Sykes, MD, Thomas R. Spitzer, MD

Blood (2007) 110 (11): 5088.

https://doi.org/10.1182/blood.V110.11.5088.5088

Published: 2007

Journal Articles

In Vivo and Ex Vivo T-Cell Depleted (TCD) NonmyeloablativeHaploidentical Stem Cell Transplantation (NSCT) for Hematologic Malignancy (HM).

Thomas R. Spitzer, MD, Steven L. McAfee, MD, Dey R. Bimalangshu, MD, Karen Ballen, MD, Eyal Attar, MD, Christine Colby, PharmD, Fred Preffer, PhD, Susan Saidman, PhD, Juanita Shaffer, David H. Sachs, MD, Megan Sykes, MD

Blood (2005) 106 (11): 5431.

https://doi.org/10.1182/blood.V106.11.5431.5431

Published: 2005

Journal Articles

Outcomes of Patients with Engraftment Syndrome (ES) Following Nonmyeloablative Hematopoietic Stem Cell Transplant (SCT) for Hematologic Malignancy(HM).

Erica Linden, MD, Steven L. McAfee, MD, Bimalangshu R. Dey, MD, Karen Ballen, MD, Susan Saidman, PhD, Christine Colby, PharmD, Megan Sykes, MD, Thomas R. Spitzer, MD

Blood (2005) 106 (11): 3661.

https://doi.org/10.1182/blood.V106.11.3661.3661

Published: 2005

Journal Articles

Development of Late over Early Full Donor Chimerism (FDC) Results in Improved Progression-Free and Overall Survival in Patients with Advanced Malignant Lymphomas Receiving Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

David T. Ting, MD, Bimalangshu Dey, MD, Ahmed Chaudhary, Christine Colby, Karen Power, Steven McAfee, MD, Karen Ballen, MD, Eyal Attar, MD, Susan Saidman, Frederick Preffer, Robert Sackstein, MD, PhD, Juanita Shaffer, Megan Sykes, MD, Thomas R. Spitzer, MD

Blood (2005) 106 (11): 3665.

https://doi.org/10.1182/blood.V106.11.3665.3665

Published: 2005

Journal Articles

Influence of First-Line Regimens on the Outcomes of High-Dose Chemotherapy with Autologous Hematopoietic Stem-Cell Transplantation for Patients with Newly Diagnosed Multiple Myeloma.

Bimalangshu R. Dey, MD, Benjamin Cox, A. Jo Chien, Martin Caron, Steven L. McAfee, MD, Christine Colby, PharmD, Thomas R. Spitzer, MD

Blood (2004) 104 (11): 931.

https://doi.org/10.1182/blood.V104.11.931.931

Published: 2004

NARROW

Non-Myeloablative T-Cell Depleted (TCD) Haploidentical Hematopoietic Cell Transplantation (HCT) Followed by Donor Leukocyte Infusion(s) for Hematologic Malignancies: The MGH Experience.

In Vivo and Ex Vivo T-Cell Depleted (TCD) NonmyeloablativeHaploidentical Stem Cell Transplantation (NSCT) for Hematologic Malignancy (HM).

Outcomes of Patients with Engraftment Syndrome (ES) Following Nonmyeloablative Hematopoietic Stem Cell Transplant (SCT) for Hematologic Malignancy(HM).

Development of Late over Early Full Donor Chimerism (FDC) Results in Improved Progression-Free and Overall Survival in Patients with Advanced Malignant Lymphomas Receiving Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

Influence of First-Line Regimens on the Outcomes of High-Dose Chemotherapy with Autologous Hematopoietic Stem-Cell Transplantation for Patients with Newly Diagnosed Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Non-Myeloablative T-Cell Depleted (TCD) Haploidentical Hematopoietic Cell Transplantation (HCT) Followed by Donor Leukocyte Infusion(s) for Hematologic Malignancies: The MGH Experience.

In Vivo and Ex Vivo T-Cell Depleted (TCD) NonmyeloablativeHaploidentical Stem Cell Transplantation (NSCT) for Hematologic Malignancy (HM).

Outcomes of Patients with Engraftment Syndrome (ES) Following Nonmyeloablative Hematopoietic Stem Cell Transplant (SCT) for Hematologic Malignancy(HM).

Development of Late over Early Full Donor Chimerism (FDC) Results in Improved Progression-Free and Overall Survival in Patients with Advanced Malignant Lymphomas Receiving Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

Influence of First-Line Regimens on the Outcomes of High-Dose Chemotherapy with Autologous Hematopoietic Stem-Cell Transplantation for Patients with Newly Diagnosed Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only